On February 28, 2024 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, reported that the Company will participate in fireside chats at two upcoming investor conferences (Press release, BeiGene, FEB 28, 2024, View Source [SID1234640630]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:50 am ET; and

Leerink Partners Global Biopharma Conference on Monday, March 11th, 2024 at 10:00 am ET

Live webcasts of these events can be accessed from the investors section of BeiGene’s website at View Source, View Source, View Source Archived replays will be available for 90 days following the event.

On February 28, 2024 Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, reported a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials (Press release, Sarah Cannon Research Institute, FEB 28, 2024, View Source [SID1234640629]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Working together, SCRI and AstraZeneca will implement modern solutions to accelerate clinical trial delivery timelines, reduce site burden, and enhance U.S. enrollment.

Genospace, a precision medicine platform, and SCRI Development Innovations collaborated on the development of a proprietary technology to seamlessly integrate data from the Electronic Health Record (EHR) to the Electronic Data Capture (EDC), EHR2EDC (E2E) systems for clinical trial data collection. To date, this advancement is decreasing site-based data entry time, reducing manual labor, lowering monitoring costs, improving data quality, and accelerating clinical trial decision-making overall.

Advancements of E2E and the focus on the deployment of SCRI’s new model will enable the synchronization of end-to-end clinical research management connecting more than 1,300 physicians who are providing access to clinical trials across multiple tumor types at more than 250 locations in 24 states across the U.S and reaching 1 in 5 patients with cancer through its affiliated sites.

"Improving end-to-end research operations will have great impact on the industry’s ability to increase the pace of drug development, without compromising quality," said Dee Anna Smith, Chief Executive Officer, SCRI. "Our collaboration with AstraZeneca has the potential to accelerate our mutual efforts to bring novel therapies to more people with cancer, through more physicians, across even more communities."

The traditional clinical trial delivery model and typical operational processes must evolve for research sites to keep pace with an increasingly complex drug development industry.

"Our ongoing commitment to personalized and effective medical interventions to people living with cancer means we are continually innovating to improve accessibility to trial participation and meet the current and future needs of clinical trial execution," said Michele Sample, Vice President, Clinical Operations, Oncology R&D, AstraZeneca. "Working with SCRI to enhance U.S. enrollment and streamline clinical trial data collection is a tremendous opportunity to increase the diversity of clinical trial participants in the U.S. and accelerate clinical trial delivery timelines. Our ambition is to bring new treatments to all patients more efficiently."

On February 28, 2024 Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, reported that it will be presenting at the upcoming B. Riley Securities’ Radiopharma Investor Conference (Press release, Blue Earth Therapeutics, FEB 28, 2024, View Source [SID1234640628]). The event will be held in New York, N.Y., on March 1, 2024. David Gauden, D. Phil., Chief Executive Officer of Blue Earth Diagnostics and Blue Earth Therapeutics, will present an overview of Blue Earth Therapeutics from 8:00 – 8:30 a.m. ET and participate in an expert panel discussion, "Opportunities and Challenges in 2024, Perspectives from Leaders in Radiopharma," from 9:15 – 9:50 a.m. ET. Dr. Dan Stevens, Vice President Clinical Development and Medical, Blue Earth Therapeutics, will participate in an expert panel, "Good But Not the Best Yet: Drug Designs to Beat Standard of Care," from 1:45 – 2:20 p.m. ET. The Company will also host 1:1 investor meetings at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Blue Earth Therapeutics continues to expand our leadership position in the rapidly growing area of radiopharmaceuticals," said David Gauden., D.Phil., Chief Executive Officer of the Company. "We are strongly positioned for continued progress across this exciting sector, and we look forward to sharing information about our innovative approach and next generation targeted radioligand therapy (RLT) technology at this important B. Riley Securities conference."

On February 28, 2024 Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, reported new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024 (Press release, Naveris, FEB 28, 2024, View Source [SID1234640627]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NavDx is the first and only clinically validated circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test that aids in the detection of HPV-driven cancer. The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease. Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications.

"We are thankful for the opportunity provided by ASTRO to share the latest findings, which emphasize the pivotal role of NavDx in influencing clinical management," commented Barry M. Berger, M.D., Chief Medical Officer at Naveris. "The data being showcased highlight the critical role circulating tumor HPV DNA assessment can play in shaping patient care strategies. We are enthusiastic about the progress made through our extensive collaborations with a diverse array of partners in the oncology community," he concluded.

These presentations showcase the utility of NavDx in the management of HPV-driven head and neck cancer at every stage of disease, from treatment response and guidance to surveillance and detection of recurrence:

127: Implications of rapid molecular responses to induction chemotherapy (IC) in Human Papilloma Virus (HPV) head and neck squamous cell carcinoma (HNSCC).
Presenting Author: Misiukiewicz, K.
Session, Date/Time: Poster Session I | February 29, 2024 | 3:00 PM – 3:30 PM MT
112: Comparison of TTMV-HPV DNA to Gold Standard PET for Evaluation of Treatment Response in HPV-Associated Oropharyngeal Cancer after Definitive Treatment
Presenting Author: Song, R.
Session, Date/Time: Poster Session I | February 29, 2024 | 3:00 PM – 3:30 PM MT
152: Tumor Tissue Modified Viral HPV DNA Monitoring in Patients with Recurrent, Metastatic HPV-driven Oropharyngeal Cancer
Presenting Author: Hanna, G. J.
Session, Date/Time: Poster Session II | February 29, 2024 | 4:45 PM – 5:45 PM MT
177: Prospective Study of Plasma Biomarker-Guided Surveillance of HPV-positive Oropharynx Cancer Using TTMV-HPV DNA: The SPHERE Study
Presenting Author: Rettig, E. M.
Session, Date/Time: Poster Session II | February 29, 2024 | 4:45 PM – 5:45 PM MT
132: Detectable Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Non-Oropharyngeal Head and Neck Cancers
Presenting Author: Duffy, E. W.
Session, Date/Time: Poster Session I | February 29, 2024 | 3:00 PM – 3:30 PM MT
Naveris will also be hosting an Industry Expert Theater at the meeting, focusing on the role of NavDx in optimizing post-treatment surveillance and monitoring for molecular residual disease:

Action to Insights: A Case-Based Discussion of the Role of NavDx in Post-treatment Surveillance of HPV-Driven OPSCC
Moderator: Marshall Posner, MD
Presenters: Meghan T. Turner, MD, and Adam Raben, MD
Session, Date/Time: Thursday, February 29, 2024 | 5:30pm MT
Naveris and NavDx will be on exhibit at ASTRO MHNCS 2024 at Booth #4.

On February 28, 2024 Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, reported that its management team will participate in the following upcoming investor conferences in March (Press release, Arcus Biosciences, FEB 28, 2024, View Source [SID1234640626]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Leerink Global Biopharma Conference 2024
Date: Monday, March 11th, 2024 at 4:00 p.m. ET
Location: Miami Beach, FL
Format: Fireside Chat

Barclays 26th Annual Global Healthcare Conference
Date: Tuesday, March 12th, 2024 at 2:35 p.m. ET
Location: Miami Beach, FL
Format: Fireside Chat

Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following each live event.